These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33086052)

  • 1. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.
    Richters A; Doyle SK; Freeman DB; Lee C; Leifer BS; Jagannathan S; Kabinger F; Koren JV; Struntz NB; Urgiles J; Stagg RA; Curtin BH; Chatterjee D; Mathea S; Mikochik PJ; Hopkins TD; Gao H; Branch JR; Xin H; Westover L; Bignan GC; Rupnow BA; Karlin KL; Olson CM; Westbrook TF; Vacca J; Wilfong CM; Trotter BW; Saffran DC; Bischofberger N; Knapp S; Russo JW; Hickson I; Bischoff JR; Gottardis MM; Balk SP; Lin CY; Pop MS; Koehler AN
    Cell Chem Biol; 2021 Feb; 28(2):134-147.e14. PubMed ID: 33086052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
    Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
    Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
    Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
    Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells.
    Hu Q; Poulose N; Girmay S; Helevä A; Doultsinos D; Gondane A; Steele RE; Liu X; Loda M; Liu S; Tang DG; Mills IG; Itkonen HM
    RNA Biol; 2021 Nov; 18(sup2):722-729. PubMed ID: 34592899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    Morel KL; Hamid AA; Clohessy JG; Pandell N; Ellis L; Sweeney CJ
    Mol Cancer Res; 2021 Jul; 19(7):1137-1145. PubMed ID: 33863813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
    Li H; Xie N; Gleave ME; Dong X
    Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.
    Gao X; Liang J; Wang L; Zhang Z; Yuan P; Wang J; Gao Y; Ma F; Calagua C; Ye H; Voznesensky O; Wang S; Wang T; Liu J; Chen S; Liu X
    Mol Oncol; 2021 Jul; 15(7):1901-1920. PubMed ID: 33932081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.